EP Patent

EP3125873B1 — Disintegrating monolithic modified release tablets containing quadri-layer extended release granules

Assigned to Pharmaquest International Center LLC · Expires 2020-06-03 · 6y expired

What this patent protects

Patent listed against dextromethorphan-hydrobromide.

Drugs covered by this patent

dextromethorphan-hydrobromide (DEXTROMETHORPHAN HYDROBROMIDE)

Patent Metadata

Patent number: EP3125873B1
Jurisdiction: EP
Classification: —
Expires: 2020-06-03
Drug substance claim: No
Drug product claim: No
Assignee: Pharmaquest International Center LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.